US panel to decide who should get the first COVID-19 shots
An influential scientific panel on Tuesday is set to tackle one of the most pressing questions in the U.S. coronavirus epidemic: When the first doses of COVID-19 vaccine become available, who should be at the front of the line for shots
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An influential scientific panel on Tuesday was set to tackle one of the most pressing questions in the U.S. coronavirus outbreak: Who should be at the front of the line when the first vaccine shots become available?
The U.S. government's Advisory Committee on Immunization Practices scheduled an open-to-the-public, virtual meeting to vote on a proposal that would give priority to health care workers and nursing home patients.
The two groups together represent around 23 million Americans out of a U.S. population of about 330 million.
Later this month, the Food and Drug Administration will consider approval of two vaccines made by Pfizer and Moderna. Current estimates project that no more than 20 million doses of each vaccine will be available by the end of 2020. And each product requires two doses.
As a result, the shots will be rationed in the early stages.
The panel will meet again at some point to decide who should be next in line. Among the possibilities: teachers, police, firefighters and workers in other essential fields such as food production and transportation; the elderly; and people with underlying medical conditions.
Experts say the vaccine will probably not become widely available in the U.S. until the spring.
The 15-member panel of outside experts, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention, who almost always approves them.
The recommendations are not binding, but for decades they have been widely heeded by doctors, and they have determined the scope and funding of U.S. vaccination programs.
It will be up to state authorities whether to follow the guidance. It will also be left to them to make further, more detailed decisions if necessary — for example, whether to put emergency room doctors and nurses ahead of other health care workers if vaccine supplies are low.
The outbreak in the U.S. has killed nearly 270,000 people and caused more than 13.5 million confirmed infections, with deaths, hospitalizations and cases rocketing in recent weeks.
About 2 million people are living in nursing homes and other U.S. long-term care facilities. Those patients and the staff members who care for them have accounted for 6% of the nation’s coronavirus cases and a staggering 39% of the deaths, CDC officials say.
The number of health care workers covered by the panel's recommendation would be about 21 million.
That's a broad category that includes medical staff who care for — or come in contact with — patients in hospitals, nursing homes, clinics and doctor’s offices. It also includes home health care workers and paramedics. Depending on how state officials apply the panel's recommendations, it could also encompass janitorial staff, food service employees and medical records clerks.
The government estimates people working in health care account for 12% of U.S. COVID-19 cases but only about 0.5% of deaths. Experts say it’s imperative to keep health care workers on their feet so that they can administer the shots and tend to the booming number of infected Americans.
For months, members of the immunization panel had said they wouldn't take a vote until the FDA approved a vaccine. That is customary procedure for the panel, with some exceptions, such as during a flu outbreak in 2009. But late last week, the group suddenly scheduled an emergency meeting for Tuesday.
The panel's chairman, Dr. Jose Romero, said the decision stemmed from a realization that the states are facing a Friday deadline to place initial orders for the Pfizer vaccine and determine where they should be delivered. The committee decided to meet now to give state and local officials guidance, he said.
But some panel members and other experts had also grown concerned by comments from Trump administration officials that suggested differing vaccine priorities.
Dr. Deborah Birx of the White House coronavirus task force said in a meeting with CDC officials last month that people 65 and older should go to the head of the line, according to a federal official who was not authorized to discuss the matter and spoke to The Associated Press on condition of anonymity.
Then last week U.S. Health and Human Services Secretary Alex Azar stressed that ultimately governors will decide who in their states gets the shots. Vice President Mike Pence echoed that view.
The comments churned up long-standing concerns during the Trump administration that vaccination decisions would be dictated by political concerns instead of science.
Asked whether Azar's comment played a role in the scheduling of the meeting, Romero said; “We don’t live in a bubble. We know what he said. But that wasn’t the primary reason this is being done.”
Jason Schwartz, a professor of health policy at the Yale School of Public Health, said it makes sense for the panel to take the unusual step of getting its recommendation out first.
“Without that formal recommendation, it does create a void from which states could go off in all sorts of different directions,” said Schwartz, who is not on the panel.
HHS officials have said they will distribute initial doses to states based on population, and it's possible some states won't receive enough to cover all of their health care workers and nursing home residents.
As a result, governors may have to decide which health care workers or which regions get shots first, Schwartz said.
“It's up to states to figure out the more granular detail,” he said.